Chicago, IL 的 伯基特淋巴瘤 臨床試驗
15 項針對 伯基特淋巴瘤 的研究正在 Chicago（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
招募中1 期
- Lurie Children's Hospital, Chicago
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
招募中3 期
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- 還有 1 項
Blinatumomab Consolidation in Real World
招募中觀察性研究歡迎健康志工
- Northwestern University, Chicago
- The University of Chicago, Chicago
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
招募中2 期
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
招募中2 期
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
招募中3 期
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
招募中1/2 期
- Research Site, Chicago
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
招募中2 期
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
招募中1/2 期
- Research Site, Chicago
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
招募中2 期
- University of Chicago Comprehensive Cancer Center, Chicago
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
招募中1 期
- University of Chicago Comprehensive Cancer Center, Chicago
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
招募中1/2 期
- University of Chicago, Chicago
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
招募中
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
其他城市的 伯基特淋巴瘤 試驗
- Houston, TX21 項研究
- Philadelphia, PA16 項研究
- Milwaukee, WI16 項研究
- Cincinnati, OH13 項研究
- New York City, NY13 項研究
- Atlanta, GA12 項研究
- Aurora, CO11 項研究
- Seattle, WA11 項研究
- Durham, NC10 項研究
- Boston, MA10 項研究
- Kansas City, MO10 項研究
- Los Angeles, CA10 項研究
Chicago 的其他研究
- 非小細胞肺癌61 項研究
- 乳癌59 項研究
- 癌症（所有類型）51 項研究
- 轉移性癌症45 項研究
- 前列腺癌45 項研究
- 肺癌41 項研究
- 肥胖症41 項研究
- 卵巢癌36 項研究
- 大腸直腸癌34 項研究
- 中風34 項研究
- 心臟衰竭31 項研究
- 過重29 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。